Semax Low Dose
Overview
Lower doses can promote relaxation while maintaining mental clarity.
Reported benefits
Relaxation with clarity, stress reduction, improved rest
Protocols & dosing
Typical dosage: 100-200 mcg (evening).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Semax Low Dose is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed Semax Low Dose from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place Semax Low Dose on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 2 — July 24, 2026. PCAC agenda: DSIP (Emideltide), Semax, Epitalon. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.
| Country | Status |
|---|---|
| United States | Category 2 removed — compounding permitted with Rx (as of Apr 22, 2026) |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Well-tolerated at low doses
References
No external sources have been catalogued for this article yet.
Related peptides
- Cerebrolysin — Neural restoration during sleep
- Cortexin — Neuropeptide for rest
- DSIP — Delta sleep-inducing peptide
- Epithalon — Circadian rhythm regulator
- GHK-Cu — Recovery enhancement peptide
- Glycine Peptide — Sleep quality amino peptide